Analyst Price Targets — JBIO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 11, 2026 5:24 pm | — | Jefferies | $48.00 | $22.34 | TheFly | Jade Biosciences price target raised to $48 from $40 at Jefferies |
| August 10, 2026 3:46 pm | Laura Chico | Wedbush | $47.00 | $21.88 | StreetInsider | Jade Biosciences (JBIO) PT Raised to $47 at Wedbush |
| June 15, 2026 9:30 am | — | UBS | $45.00 | $15.34 | TheFly | Jade Biosciences initiated with a Buy at UBS |
| June 2, 2026 10:54 am | — | Piper Sandler | $55.00 | $18.59 | StreetInsider | Jade Biosciences (JBIO) PT Raised to $55 at H.C. Wainwright |
| June 2, 2026 10:51 am | Vamil Divan | Guggenheim | $47.00 | $18.59 | TheFly | Jade Biosciences price target raised to $47 from $32 at Guggenheim |
| May 11, 2026 11:46 am | Laura Chico | Wedbush | $34.00 | $25.81 | TheFly | Jade Biosciences price target raised to $34 from $24 at Wedbush |
| May 11, 2026 11:24 am | — | Guggenheim | $32.00 | $25.81 | TheFly | Jade Biosciences price target raised to $32 from $23 at Guggenheim |
| April 27, 2026 10:14 am | — | H.C. Wainwright | $45.00 | $24.98 | TheFly | Jade Biosciences price target raised to $45 from $35 at H.C. Wainwright |
| March 6, 2026 5:15 pm | Alex Thompson | Stifel Nicolaus | $40.00 | $14.07 | StreetInsider | Jade Biosciences (JBIO) PT Raised to $40 at Stifel: "We like the setup for JADE101" |
| January 7, 2026 11:07 am | — | H.C. Wainwright | $25.00 | $13.17 | TheFly | Jade Biosciences initiated with a Buy at H.C. Wainwright |
Latest News for JBIO
SAN FRANCISCO and VANCOUVER, British Columbia, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the following upcoming conferences: Wells Fargo 21st Annual Healthcare Conference Fireside Chat: Tuesday, September 8 at 3:45…
Jade Biosciences (JBIO) targets IgAN with JADE101, aiming for quarterly dosing that could significantly improve patient adherence versus competitors' more frequent regimens. Phase 1 data show JADE101 achieves ~70% IgA reduction with a favorable safety profile; Phase 2 JUNIPER trial interim data expected in 2027 will be pivotal. JBIO's pipeline includes JADE201 (anti-BAFF-R antibody) and JADE301 (IFN-beta inhibitor),…
Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy Phase 2 JADE101 clinical trial in IgA nephropathy underway; interim data expected in 2027 Phase 3 JADE101 registrational trial in IgA nephropathy expected to begin in the first half of 2027 Began dosing participants with rheumatoid arthritis in…
SAN FRANCISCO and VANCOUVER, British Columbia, June 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the appointment of Mark Eisner, M.D., M.P.H., to its Board of Directors, effective June 25, 2026.
SAN FRANCISCO and VANCOUVER, British Columbia, June 05, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it has closed its previously announced public offering of 11,500,000 shares of its common stock, including 1,500,000 shares sold pursuant to…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for JBIO.
U.S. House Trading
No House trades found for JBIO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.